WASHINGTON, D.C. — Given Republicans’ hardening opposition to health care reform, Democrats say they see little chance for bipartisan legislation to fix the nation’s health care system this fall, according to the New York Times.
Top Democrats said Tuesday that their go-it-alone attitude was being shaped by Republicans’ increasingly strident opposition to reform legislation during the summer recess for Congress, the Times said. Some Republicans have used town hall meetings to tell constituents they think reform legislation is flawed beyond repair. So Democrats are increasingly focused on drawing support for their final reform plan from their own ranks, according to the Times.
White House chief of staff Rahm Emmanual said the heated opposition shows Republicans have drawn their line in the sand against any health care changes, the latest opposition campaign against efforts led by President Obama, a Democrat, the Times said. The Democratic shift to a singular attitude may not help pass health care legislation any better or faster, according to the Times. The political party still must reconcile differences between liberal members — determined to win a government-run insurance option that would compete against private insurers — and conservative members, who are worried about the cost and scope of the legislation, to pass reform measures, the Times said.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
On the other hand, Democrats’ willingness to push through legislation without support of Republicans could change the dynamics around health reform and even change the final substance of the bill, according to the Times. Democrats might be able to move ahead more quickly if they don’t have to worry about bipartisan support of the legislation, the Times said.
Meanwhile, the White House interpreted critical comments made by Sen. Chuck Grassley, the Iowa Democrat who co-leads the Senate Finance Committee— the powerful group of six senators who had tried to craft bipartisan reform prior to breaking for the summer — as evidence that there is little chance of reaching agreement on reform, the Times said. Grassley, who may face a Republican party challenge next year, has gotten an earful traveling around his state, according to the Times. Grassley told CNBC this week that he will vote against a bill unless it has broad support from Republicans, even if it has all the provisions he wants, the Times said.
Liberal activists have been pressuring Senate Democrats to move ahead with their own plans for health care reform regardless of Grassley’s opposition, according to The Hill.
More stories that are worth a read:
Using Informed Awareness to Transform Care Coordination and Improve the Clinical and Patient Experience
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
- Surgeon who led tainted study is leaving his job (Minneapolis/St. Paul Star Tribune)
- Senator moves to stop scientific ghostwriting (New York Times)
- GOP leader to drug industry: You made a deal with a bully (Wall Street Journal Health blog)
- Obama’s health care tradeoff (Chicago Tribune)
- Study using embryonic stem cells is delayed (New York Times)
- Lilly shelves osteoporosis drug after five-year study (Indianapolis Star)
- Why Big Pharma wants to be like Big Biotech (Xconomy)
- Thomson Reuters study finds impact of recession easing on hospitals (PRNewswire)
- Med mart developer Chris Kennedy won’t run for U.S. Senate in Illinois( Crain’s Cleveland Business)
- Emergence of newer drug classes to treat diabetes and co-morbidities key to market expansion, reveals Frost & Sullivan (PRNewswire)
- A lesson plan for swine flu (Columbus Dispatch)
- Cleveland: Northeast Ohio stem cell research is cutting edge (WKYC)
- Case Western Reserve University changing how it trains doctors (WKYC)
- St. Jude Medical lays off 200 across country (Minneapolis-St. Paul Star Tribune)
- 18 hospitals with great neurosurgery programs (Becker’s Hospital Review)
- How do you ask your doctor if he gets paid by the drug industry? (Wall Street Journal Health blog)